Renāte Kērda Brings Directorial Debut SALA to Liepāja Theatre
Kērda serves as the author, director, playwright, and visual and musical designer for the new work titled SALA, marking the venue’s first new production of the season. Her previous works have toured across 15 countries in Europe, Asia, and Scandinavia, earning international festival recognition along with the Estonian Cultural Endowment’s annual theatre prize and multiple Estonian Theatre Awards nominations and wins.
Valters Sīlis on the Long-Awaited Collaboration
Liepāja Theatre artistic director Valters Sīlis stated that bringing Kērda to Latvia was a long-cherished dream, noting that seeing her productions in Estonia offers an unpredictable yet joyful theatrical journey. According to Sīlis, Kērda’s works stand out for searching for a truly poetic stage language infused with small and large theatrical discoveries and a consistent sense of humor. Kērda constructs her performances as unified works of art where all elements interconnect to serve a single core idea, focusing her creative output on human existence, its absurdities, and social phenomena.
Did you know? Renāte Kērda’s signature style is autorteātris, meaning she routinely takes on multiple creative roles—including direction, playwriting, and visual and musical design—to build her productions as cohesive artistic statements.
The Poetic Metaphor of SALA
The title SALA utilizes a deliberate play on words, as the term can function as either a noun or a verb depending on viewer interpretation. Kērda described the upcoming production as a poem and a social allegory concerning contemporary society, stating that she wants to offer audiences a clean-slate experience based purely on the title. Kērda explained her vision by asking why anyone would deign to explain a poem before it is experienced, or hand over a solved crossword puzzle, noting that an island can represent a physical location, a distance, a boundary, or an internal state of mind.
Production Cast and Creative Team
The cast for SALA features actors Polina Čerņenoka, Edgars Ozoliņš, Gatis Maliks, Hugo Puriņš, and Kārlis Ērglis, with lighting design handled by Mārtiņš Feldmanis. Rehearsals at the Liepāja Theatre began in late July ahead of the September opening night.
Frequently Asked Questions
When is the premiere of SALA at Liepāja Theatre?
The premiere takes place on September 26, serving as the Liepāja Theatre’s first new production of the season.
Who is the director of SALA?
The production is directed, written, and visually and musically designed by Estonian theatre artist Renāte Kērda.
Who stars in the cast of SALA?
The cast includes actors Polina Čerņenoka, Edgars Ozoliņš, Gatis Maliks, Hugo Puriņš, and Kārlis Ērglis.
What are your thoughts on auteur theatre productions coming to Latvian stages? Share your perspective in the comments below, explore our other theatre news, or subscribe to our newsletter for upcoming reviews.
- Emmy Awards 2026 Winners: Noah Wyle, Jean Smart & Widow’s Bay Dominate
- Macklemore Dropped from Ed Sheeran Tour Over Pro-Palestine Comments
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)